Esperion Therapeutics, Inc.
NASDAQ:ESPR · NASDAQ Global Market
+$0.00 today
Vol 17.00M · Avg 12.29M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ESPR · Revenue to Net Income
Key Ratios
Analysis
$418.2M of revenue converted into -$7.4M of net income for the selected period. Gross margin is 60.5% and net margin is -11.5%, showing how much revenue survives after costs and taxes. EPS is $-0.06, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $403.1M +21.3% | $332.3M +185.7% | $116.3M +54.1% | $75.5M -3.8% | $78.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $129.2M +88.4% | $68.6M +58.6% | $43.3M +60.4% | $27.0M +89.7% | $14.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $273.9M +3.9% | $263.7M +260.9% | $73.1M +50.6% | $48.5M -24.5% | $64.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 67.9% -11.4pp | 79.4% +16.5pp | 62.8% -1.5pp | 64.3% -17.6pp | 81.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $47.9M +3.5% | $46.2M -46.3% | $86.1M -27.6% | $118.9M +12.2% | $106.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $165.8M +1.7% | $163.1M +14.4% | $142.5M +30.7% | $109.1M -41.0% | $185.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $213.6M +2.1% | $209.3M -8.4% | $228.6M +0.3% | $228.0M -21.6% | $291.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $105.0K +66.7% | $63.0K -61.6% | $164.0K -67.2% | $500.0K -18.3% | $612.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | $63.9M +743.8% | $7.6M +105.0% | -$150.1M +14.9% | -$176.3M +20.6% | -$222.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 15.8% +13.6pp | 2.3% +131.3pp | -129.0% +104.6pp | -233.7% +49.5pp | -283.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $60.3M +10.8% | $54.4M +135.0% | -$155.6M +13.3% | -$179.5M +20.8% | -$226.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 15.0% -1.4pp | 16.4% +150.1pp | -133.7% +104.1pp | -237.8% +51.2pp | -289.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $3.5M | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $84.6M +42.8% | $59.3M +0.5% | $59.0M +3.8% | $56.8M +22.6% | $46.4M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$81.1M +23.6% | -$106.1M -97.7% | -$53.7M +0.9% | -$54.2M -27.8% | -$42.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$20.8M +59.7% | -$51.7M +75.3% | -$209.2M +10.4% | -$233.7M +13.2% | -$269.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -5.2% +10.4pp | -15.6% +164.3pp | -179.9% +129.7pp | -309.6% +33.5pp | -343.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.8M | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$22.7M +56.2% | -$51.7M +75.3% | -$209.2M +10.4% | -$233.7M +13.2% | -$269.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | -5.6% +9.9pp | -15.6% +164.3pp | -179.9% +129.7pp | -309.6% +33.5pp | -343.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +60.7% | -$0 +86.2% | -$2 +53.1% | -$4 +60.7% | -$11 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +60.7% | -$0 +86.2% | -$2 +53.1% | -$4 +60.7% | -$11 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $207.9M +11.0% | $187.2M +81.5% | $103.1M +55.3% | $66.4M +129.8% | $28.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $207.9M +11.0% | $187.2M +81.5% | $103.1M +55.3% | $66.4M +129.8% | $28.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Absci Corporation
NASDAQ:ABSI
$1.14B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$991.47M
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$801.41M
Aquestive Therapeutics, Inc.
NASDAQ:AQST
$462.58M
REGENXBIO Inc.
NASDAQ:RGNX
$417.20M
Emergent BioSolutions Inc.
NYSE:EBS
$411.48M
Orthofix Medical Inc.
NASDAQ:OFIX
$373.16M
SNDL Inc.
NASDAQ:SNDL
$368.17M
SIGA Technologies, Inc.
NASDAQ:SIGA
$308.05M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ESPR generate?
Esperion Therapeutics, Inc. (ESPR) reported $403.13M of revenue in fiscal 2025.
Is ESPR profitable?
Esperion Therapeutics, Inc. (ESPR) reported -$22,682,000.00 of net income, with a net margin of -5.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.